148 related articles for article (PubMed ID: 30190928)
1. Interferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experience.
Oliver DE; Sondak VK; Strom T; Zager JS; Naghavi AO; Sarnaik A; Messina JL; Caudell JJ; Trotti AM; Torres-Roca JF; Khushalani NI; Harrison LB
Melanoma Manag; 2018 Jun; 5(1):MMT02. PubMed ID: 30190928
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Therapy for Stage III Melanoma Without Immediate Completion Lymph Node Dissection.
Torphy RJ; Friedman C; Ho F; Leonard LD; Thieu D; Lewis KD; Medina TM; Robinson WA; Gonzalez RC; Stewart CL; Kounalakis N; McCarter MD; Gleisner A
Ann Surg Oncol; 2022 Feb; 29(2):806-815. PubMed ID: 34537899
[TBL] [Abstract][Full Text] [Related]
3. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A;
Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144
[TBL] [Abstract][Full Text] [Related]
4. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
Nowecki ZI; Rutkowski P; Michej W
Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
[TBL] [Abstract][Full Text] [Related]
5. Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node.
Leiter U; Stadler R; Mauch C; Hohenberger W; Brockmeyer NH; Berking C; Sunderkötter C; Kaatz M; Schatton K; Lehmann P; Vogt T; Ulrich J; Herbst R; Gehring W; Simon JC; Keim U; Verver D; Martus P; Garbe C;
J Clin Oncol; 2019 Nov; 37(32):3000-3008. PubMed ID: 31557067
[TBL] [Abstract][Full Text] [Related]
6. Lymph node status and survival in cutaneous malignant melanoma--sentinel lymph node biopsy impact.
Rutkowski P; Nowecki ZI; Nasierowska-Guttmejer A; Ruka W
Eur J Surg Oncol; 2003 Sep; 29(7):611-8. PubMed ID: 12943629
[TBL] [Abstract][Full Text] [Related]
7. Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy.
Lee RJ; Gibbs JF; Proulx GM; Kollmorgen DR; Jia C; Kraybill WG
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):467-74. PubMed ID: 10661355
[TBL] [Abstract][Full Text] [Related]
8. Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy.
McMasters KM; Egger ME; Edwards MJ; Ross MI; Reintgen DS; Noyes RD; Martin RC; Goydos JS; Beitsch PD; Urist MM; Ariyan S; Sussman JJ; Davidson BS; Gershenwald JE; Hagendoorn LJ; Stromberg AJ; Scoggins CR
J Clin Oncol; 2016 Apr; 34(10):1079-86. PubMed ID: 26858331
[TBL] [Abstract][Full Text] [Related]
9. BRAF mutation correlates with worse local-regional control following radiation therapy in patients with stage III melanoma.
Wolfe AR; Chablani P; Siedow MR; Miller ED; Walston S; Kendra KL; Wuthrick E; Williams TM
Radiat Oncol; 2021 Sep; 16(1):181. PubMed ID: 34537078
[TBL] [Abstract][Full Text] [Related]
10. The analysis of the outcomes and factors related to iliac-obturator involvement in cutaneous melanoma patients after lymph node dissection due to positive sentinel lymph node biopsy or clinically detected inguinal metastases.
Zdzienicki M; Rutkowski P; Nowecki ZI; van Akkooi AC; Michej W; Dziewirski W; Świtaj T; Pieńkowski A; Sałamacha M; Bylina E; Eggermont AM
Eur J Surg Oncol; 2013 Mar; 39(3):304-10. PubMed ID: 23298828
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial.
Eggermont AMM; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbe C; Ferraresi V; Smylie M; Weber JS; Maio M; Hosein F; de Pril V; Kicinski M; Suciu S; Testori A
Eur J Cancer; 2019 Sep; 119():1-10. PubMed ID: 31400634
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
Eggermont AM
Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
[TBL] [Abstract][Full Text] [Related]
13. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
Eggermont AM; Suciu S; Testori A; Santinami M; Kruit WH; Marsden J; Punt CJ; Salès F; Dummer R; Robert C; Schadendorf D; Patel PM; de Schaetzen G; Spatz A; Keilholz U
J Clin Oncol; 2012 Nov; 30(31):3810-8. PubMed ID: 23008300
[TBL] [Abstract][Full Text] [Related]
14. Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma.
Strom T; Torres-Roca JF; Parekh A; Naghavi AO; Caudell JJ; Oliver DE; Messina JL; Khushalani NI; Zager JS; Sarnaik A; Mulé JJ; Trotti AM; Eschrich SA; Sondak VK; Harrison LB
J Natl Compr Canc Netw; 2017 Apr; 15(4):473-482. PubMed ID: 28404758
[No Abstract] [Full Text] [Related]
15. Value of sentinel lymph node biopsy and adjuvant interferon treatment in thick (>4 mm) cutaneous melanoma: an observational study.
Morera-Sendra N; Tejera-Vaquerizo A; Traves V; Requena C; Bolumar I; Pla A; Vázquez C; Soriano V; Nagore E
Eur J Dermatol; 2016; 26(1):34-48. PubMed ID: 27023017
[TBL] [Abstract][Full Text] [Related]
16. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
Eggermont AM; Suciu S; Testori A; Kruit WH; Marsden J; Punt CJ; Santinami M; Salès F; Schadendorf D; Patel P; Dummer R; Robert C; Keilholz U; Yver A; Spatz A
Eur J Cancer; 2012 Jan; 48(2):218-25. PubMed ID: 22056637
[TBL] [Abstract][Full Text] [Related]
17. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H;
Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809
[TBL] [Abstract][Full Text] [Related]
18. Modern Approach to Melanoma Adjuvant Treatment with Anti-PD1 Immune Check Point Inhibitors or
Placzke J; Rosińska M; Sobczuk P; Ziętek M; Kempa-Kamińska N; Cybulska-Stopa B; Kamińska-Winciorek G; Bal W; Mackiewicz J; Galus Ł; Las-Jankowska M; Jankowski M; Dziura R; Drucis K; Borkowska A; Świtaj T; Rogala P; Kozak K; Klimczak A; Jagodzińska-Mucha P; Szumera-Ciećkiewicz A; Koseła-Paterczyk H; Rutkowski P
Cancers (Basel); 2023 Sep; 15(17):. PubMed ID: 37686659
[TBL] [Abstract][Full Text] [Related]
19. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of treatment and prognosis of 59 cases of vulvar melanoma].
Yuan GW; Li XG; Li N; Yao HW; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2020 Jun; 55(6):395-401. PubMed ID: 32842246
[No Abstract] [Full Text] [Related]
[Next] [New Search]
